Default company panoramic image
Logo

Hsiri Therapeutics, LLC

Hsiri is a start-up antibiotics company founded by two seasoned pharma executives with novel antibiotics from Dr. Marvin Miller at the University of Notre Dame.

  • Stage Product In Development
  • Industry Biotechnology
  • Location King of Prussia, PA, USA
  • Currency USD
  • Founded February 2012
  • Employees 8
  • Website hsiritherapeutics.com

Company Summary

Hsiri is developing new antibiotics in areas where bacterial resistance is a significant concern. Major pharmaceutical companies are not investing in antibiotic research. Initially, we intend to develop our compounds for licensing to these companies and other, emerging, mid-sized pharma. Ultimately, however, we intend to market one or more of the Hsiri products in niche markets with our own marketing and sales organization.

Team

  • Default avatar
    Dennis Frederick Willson
    Chairman & CEO

    Denny is a lawyer with over 30 years in the biopharm industry. He began his career in the legal department at Abbott Laboratories but later joined the international marketing group. He left Abbott to join Rorer where he ultimately became Managing Director of Rorer Spain. Prior to forming Hsiri he was a founder and CEO of Cytokine PharmaSciences, a women's health company that, after 20 years, was successfully sold to Ferring in 2011.

  • Default avatar
    William Dow Claypool
    President & COO

    Bill is a physician with over 30 years experience as a practicing pulmonologist, a researcher, a senior executive and, finally, an entrepreneur. He held management positions at Searle and SmithKline Beecham, eventually becoming worldwide head of clinical development at SKB. Bill was also president & CEO of Phoenix Data Systems, before selling the company in 2008. Prior to co-founding Hsiri, he worked as a consultant in the biopharm industry.

  • Default avatar
    Marvin Miller
    Chief Scientific Officer

    Marv is the George and Winifred Clark Professor of Chemistry and Biochemistry at the University of Notre Dame. His research has been involved in the discovery of antibiotics for the last thirty years. He is a consultant to a number of pharmaceutical companies on drug design and antibiotic discovery.

  • Default avatar
    Thais Sielecki
    Vice President, Preclinical Development

    Thais worked as Vice President, Preclinical Development of Cytokine PharmaSciences, Inc. prior to its successful sale to Ferring, and previously worked at DuPont-Merck, Bristol-Meyers Squibb and other pharmaceutical companies. She has a Ph.D. In medicinal chemistry from Colorado State University.

  • Default avatar
    Mercedes Alexander
    Controller

    Merc has over 30 years of experience in the chemical and pharmaceuticals industries. She began her career at Quaker Chemical but later joined Cytokine PharmaSciences where she worked as Director of Accounting and Administration before the company was sold to Ferring in 2011.

Advisors

  • Default avatar
    Andy Hamilton, Morgan, Lewis & Bockius
    Lawyer
    Unconfirmed
    Default avatar
    Mercedes Alexander
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    None
    Unconfirmed